# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Evel Knievel (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB001-SYN
- Date: 2026-01-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Dale Rasmussen, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for new patient: chronic pain from old fractures, diabetes, and raised liver tests with low platelets on today's tests: hepatitis C and liver work-up, NSAIDs stopped, alcohol counseling, and hepatology review booked. **S**

## Objective

Hemoglobin: 13.9 g/dL; White cell count: 4.6 10*3/uL; Platelets: 118 10*3/uL (low); Sodium: 137 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 0.92 mg/dL; eGFR (CKD-EPI 2021): 97 mL/min/1.73 m²; Glucose (fasting): 162 mg/dL (high); ALT: 88 U/L (high); AST: 96 U/L (high); Alkaline phosphatase: 104 U/L; Total bilirubin: 1.1 mg/dL; Albumin: 3.6 g/dL; INR: 1.1; Hemoglobin A1c: 7.4% (high); Total cholesterol: 186 mg/dL; LDL cholesterol: 112 mg/dL (high); HDL cholesterol: 38 mg/dL (low); Triglycerides: 178 mg/dL (high); Urine albumin-creatinine ratio: 18 mg/g; AUDIT-C: 7; PHQ-2: 1; Pain (0 to 10): 7. All results are synthetic.

BP 138/84 mmHg; pulse 80 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 86 kg; BMI 27.1 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1992 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review ordered; Type 2 diabetes on metformin, A1c 7.4%; Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioids. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Continued without change: Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Stopped: Ibuprofen 800 mg oral tablet, one tablet three times a day for joint and back pain **S**
- Stopped: Omeprazole 20 mg delayed-release oral capsule, one capsule daily for indigestion from ibuprofen **S**
- Started: Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a day **S**
- Started: Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day **S**

## Plan

- Hepatology consultation within three weeks to confirm and stage chronic liver disease and plan antiviral treatment if hepatitis C is confirmed. Guideline: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023) **S**
- Liver work-up for raised transaminases and low platelets: hepatitis C antibody with reflex RNA, hepatitis B surface antigen, core antibody and surface antibody, hepatitis A IgG, HIV, INR, ultrasound of the abdomen, and FIB-4 from today's tests. Guideline: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); Hepatitis C Virus Infection in Adolescents and Adults: Screening (2020) **S**
- Pain care safe in liver disease: stop ibuprofen and omeprazole; acetaminophen up to 2 g a day; topical diclofenac for the knees; no opioids; physical and aquatic therapy; heat, pacing and sleep routines; pain coping skills. Guideline: Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018); Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95 (PMID 36327391) (2022) **S**
- Alcohol: brief counseling toward stopping completely, because alcohol speeds liver scarring; follow-up AUDIT-C at each visit; counseling or medicine for alcohol use offered if he cannot stop. Guideline: Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018) **S**
- Falls and fractures: physical therapy and a home safety review; vitamin D; bone density scan, since cirrhosis, alcohol and many old fractures raise the risk of osteoporosis. Guideline: Watts NB, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(6):1802-1822 (PMID 22675062) (2012); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026) **S**
- Depression and distress screening at each visit, and plain explanations with written information. Guideline: CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**
